Global Male Infertility Market: Growth Analysis 2023-2030

Triton Market Research presents the Global Male Infertility Market report segmented by Test Type (Oxidative Stress Analysis, Sperm Agglutination, Computer-Assisted Semen Analysis, Sperm Penetration Assay, DNA Fragmentation Technique, Microscopic Examination, Other Test Types), Treatment (Assisted Reproductive Technology and Surgery, Medications), and Regional Outlook (North America, Asia-Pacific, Europe, Middle East and Africa, Latin America). 

The report further includes the Market Summary, Industry Outlook, Parent Market Analysis, Impact Analysis, Porter’s Five Forces Analysis, Market Maturity Analysis, Key Market Strategies, Industry Components, Regulatory Framework, Key Market Strategies, Drivers, Challenges, Opportunities, Analyst Perspective, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2023-2030).

As per Triton’s estimates, the global male infertility market is set to advance with a CAGR of 4.81% during the forecast period 2023-2030.

Male infertility is commonly attributed to problems with sperm production or delivery, encompassing low sperm production, abnormal sperm function, and blockages that impede sperm delivery. Various factors, such as illnesses, injuries, chronic health conditions, lifestyle changes, and other elements, may also contribute to male infertility.

Factors such as increasing acceptance of minimally invasive surgeries, the growing availability of infertility treatments, and government initiatives open new avenues for the male infertility market. Various governments are backing male infertility treatment by initiating programs to enhance reimbursement conditions for infertility-related procedures. Approval of diagnostic devices and determining reimbursement policies for assisted reproductive technology (ART) procedures is carried out by the Centers for Medicare and Medicaid Services (CMS).

While ART therapy has proven beneficial in infertility treatment, its growth may be restricted due to expensive procedures and the absence of coverage under most health insurance plans. Notably, approximately 75% of IVF/ICSI cycles result in failure, necessitating multiple treatment cycles and subsequently escalating the overall treatment cost. Hence, expensive treatments hinder the market’s expansion.

Asia-Pacific is anticipated to emerge as the fastest-growing region over the forecasting period. The region’s growth can be attributed to increasing disposable income, growing awareness of male infertility, technological advancements, and strategic initiatives. The region has also witnessed the establishment of various fertility clinics, which also supplements the regional male infertility market’s growth.

The notable companies thriving in the male infertility market are Zydus Lifesciences Limited, Halotech DNA, EMD Serono Inc, Sanofi SA, Endo International Plc, Bayer AG, Vitrolife, Aytu BioPharma, CinnaGen Co, and Laboratory Corporation of America Holdings.

The global male infertility market is highly competitive and is expected to remain the same during the forecast period due to the presence of numerous players. Key companies like Sanofi are dedicated to developing innovative products for infertility treatment. Additionally, market players employ strategies such as clinical trials for new male infertility products to gain a competitive edge.